GlassScriptPhysician profile
Timothy M Wheeler
NPI 1609822816
$16,096.34
in general payments reported to CMS, 2019-2025
29 companies · $753 in 2025
The $753 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,429 · 2020: $2,063 · 2021: $1,002 · 2022: $1,187 · 2023: $1,011 · 2024: $1,651 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,414.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,568.11 | 2019-2022 | |
| Davol INC. | $4,272.64 | 2019-2024 | Phasix Mesh, Capsure Permanent Fixation System |
| Ethicon US, LLC | $776.59 | 2019-2025 | Echelon; Endopath, Harmonic, Ethicon |
| Regeneron Healthcare Solutions, INC. | $337.70 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $328.86 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $318.00 | 2022-2025 | Entyvio, Gattex |
| Abbvie INC. | $275.84 | 2021-2025 | Skyrizi, Rinvoq |
| Novo Nordisk INC | $264.76 | 2023-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.87 | 2022-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $143.87 | 2022-2024 | |
| Qol Medical, LLC | $88.29 | 2024 | Sucraid |
| Ardelyx, INC. | $64.44 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $63.18 | 2024-2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $53.20 | 2023 | Dificid |
| Smith+Nephew, INC. | $40.95 | 2019-2023 | Pico 7, Renasys Go V2 Home |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $34.54 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $33.77 | 2024 | Voquezna |
| Lilly USA, LLC | $29.72 | 2024 | Omvoh |
| La Jolla Pharmaceutical Company | $28.86 | 2023 | Xerava |
| Daiichi Sankyo INC. | $23.15 | 2022 | |
| Conmed Corporation | $20.22 | 2021 | |
| Integra Lifesciences Corporation | $17.55 | 2024 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Covidien LP | $16.09 | 2019 | |
| W. L. Gore & Associates, INC. | $15.87 | 2023 | Gore Enform Preperitoneal Biomaterial |
| Organon LLC | $15.45 | 2023 | Hadlima |
| Olympus America INC. | $14.78 | 2019 | |
| Intercept Pharmaceuticals, INC. | $14.54 | 2024 | |
| Evoke Pharma, INC. | $13.09 | 2024 | |
| Reprise Biomedical, INC. | $5.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.